Condition
Lymphocytic Colitis
Total Trials
5
Recruiting
0
Active
0
Completed
2
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 77/100
Termination Rate
40.0%
2 terminated out of 5 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results50% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 2 (1)
P 3 (1)
Trial Status
Completed2
Terminated2
Unknown1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT05579444Terminated
Systems Biology of Gastrointestinal and Related Diseases
NCT00217022Phase 2TerminatedPrimary
Budesonide Versus Placebo for the Treatment of Lymphocytic Colitis
NCT01209208Phase 3CompletedPrimary
Budesonide Versus Mesalazine Versus Placebo in Lymphocytic Colitis
NCT01928667Completed
Case-Control Study to Identify Risk Factors for Microscopic Colitis
NCT01504048Not ApplicableUnknown
Usefulness of Chromoendoscopy in Diagnosing Microscopic Colitis
Showing all 5 trials